Bruker (NASDAQ:BRKR) Downgraded by Zacks Research to Hold

Bruker (NASDAQ:BRKR) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Wednesday, Zacks reports.

Several other equities analysts have also commented on BRKR. Stifel Nicolaus set a $50.00 price target on Bruker in a research report on Wednesday, August 5th. UBS Group set a $60.00 price target on shares of Bruker in a research report on Wednesday, June 24th. TD Cowen reaffirmed a “hold” rating on shares of Bruker in a report on Wednesday, July 15th. JPMorgan Chase & Co. upped their target price on Bruker from $55.00 to $65.00 and gave the company an “overweight” rating in a report on Monday, June 8th. Finally, Citigroup lowered their price target on shares of Bruker from $60.00 to $53.00 and set a “hold” rating for the company in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Bruker has a consensus rating of “Hold” and an average price target of $56.64.

Bruker Stock Performance

NASDAQ BRKR opened at $59.41 on Wednesday. The company has a market capitalization of $9.05 billion, a P/E ratio of -84.87, a PEG ratio of 1.81 and a beta of 1.26. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92. Bruker has a 1-year low of $28.95 and a 1-year high of $65.30. The business has a 50 day moving average price of $58.81 and a 200 day moving average price of $48.57.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.11. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The business had revenue of $838.50 million for the quarter, compared to the consensus estimate of $853.57 million. During the same period in the prior year, the business earned $0.32 earnings per share. The business’s revenue was up 5.2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Sell-side analysts expect that Bruker will post 2.12 EPS for the current fiscal year.

Institutional Trading of Bruker

A number of institutional investors and hedge funds have recently modified their holdings of the company. Los Angeles Capital Management LLC bought a new stake in shares of Bruker in the fourth quarter valued at about $26,000. Global Retirement Partners LLC bought a new position in shares of Bruker during the 2nd quarter worth approximately $38,000. Parallel Advisors LLC lifted its position in shares of Bruker by 121.0% during the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after buying an additional 479 shares during the period. Allworth Financial LP boosted its stake in Bruker by 40.6% in the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after buying an additional 257 shares in the last quarter. Finally, Essential Partners LLC bought a new stake in Bruker in the first quarter valued at $36,000. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.